Importantly, the current review not only covers a broad spectrum of TRAIL-related delivery systems that have recently been developed for cancer treatment, which is considered conventional for TRAIL, but it also includes those aiming at other therapeutic areas, such as autoimmune and inflammatory diseases, due to TRAIL’s important role in the regulation of immune processes. This evidence concerns the gene TNFSF10 and cancer.